Donor-specific antibodies have become an established biomarker predicting antibody-
mediated rejection. Antibody-mediated rejection is the leading cause of graft loss after …

De novo donor-specific antibody (dnDSA) develops in 15–25% of renal transplant recipients
within 5 years of transplantation and is associated with 40% lower graft survival at 10 years …

OBJECTIVE: To describe the first-year results of the first human uterus transplantation case
from a multiorgan donor. DESIGN: Case study. SETTING: University hospital. PATIENT (S) …

The role of de novo donor-specific HLA antibodies (DSA) in liver transplantation remains
unknown as most of the previous studies have only focused on preformed HLA antibodies …

Objective To report the 12-month results of the first human uterus transplantation case using
robot-assisted uterine retrieval. This type of transplantation may become a treatment for …

Kidney transplantation has evolved over more than half a century and remarkable progress
has been made in patient and graft outcomes. Despite these advances, chronic allograft …

C1q-binding ability may indicate the clinical relevance of de novo donor-specific anti-HLA
antibodies (DSA). This study investigated the incidence and risk factors for the appearance …

Background Long-term survival after lung transplant is limited by the development of chronic
and progressive airflow obstruction, a condition known as bronchiolitis obliterans syndrome …

Anti-HLA donor-specific antibodies (DSA) identified by single antigen bead array (SAB) are
questioned for their excess in sensitivity and lack of event prediction after transplantation …

Even when successfully induced, immunological tolerance to solid organs remains
vulnerable to inflammatory insults, which can trigger rejection. In a mouse model of cardiac …